*South Los Angeles-based Post & Beam, a popular full-service restaurant, is ending its long standing run at the Baldwin Hills Crenshaw Plaza, with closing its doors at the end of February. Eater Los ...
BMO Capital says the first-ever clinical data from Beam Therapeutics (BEAM)’ base editing platform in sickle cell disease, or SCD, demonstrate a “robust” efficacy and safety profile for BEAM-101 with ...
Futuristic 3D cubes showing DNA base pairs and a double helix. This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive ...
Beam Therapeutics’ experimental gene-editing therapy for sickle cell disease now has its first cut of patient data showing signs of treating the rare blood disorder in a way that could differentiate ...
A Beam Therapeutics gene-editing therapy designed to fix a mutation at the root of a rare liver protein deficiency now has early signs of efficacy along with safety data that ease some concerns about ...
I covered Beam Therapeutics (BEAM) in April last year, when the stock had a market cap of $3.7bn. Today, despite some derisking events, it has a market cap of $2.6bn. The stock price has fallen 30% as ...
I was looking forward to seeing how Beam Therapeutics would do in their clinical trials of single-base DNA editing therapies, and this morning we have a readout. It was a very small trial: three ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Beam Therapeutics announced today that it is launching to develop precision genetic medicines that make edits to individual base pairs in the genetic code.
CAMBRIDGE, Mass. & KOBE CITY, Japan--(BUSINESS WIRE)--Beam Therapeutics and Bio Palette today announced an exclusive cross-license agreement around each companies’ base editing intellectual property.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback